FDA Approves New Cervical Cancer Vaccine

by: cancercompass

The Wall Street Journal is reporting today that the U.S. Food and Drug Administration has approved the sale of Cervarix.

Cervarix is a cervical cancer vaccine produced by British drug manufacturer GlaxoSmithKline and has been approved for use in girls between 10 and 25 years of age.

The vaccine is intended to offer protection against human papillomavirus (HPV) types 16 and 18, which cause approximately 75% of cervical cancers in North America, reports The Wall Street Journal.

Cervarix will compete with Gardasil, a cervical cancer vaccine which has been sold in the United States since June 2006.

The new vaccine is expected to be available in the U.S. by the end of this year.